<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04839224</url>
  </required_header>
  <id_info>
    <org_study_id>4-2020-1491</org_study_id>
    <nct_id>NCT04839224</nct_id>
  </id_info>
  <brief_title>Comparing Between CO2 and Phenylephrine Treatment in Patients With Progressive Lacunar Infarction (CARBOGEN Study)</brief_title>
  <official_title>Comparing Between CO2 and Phenylephrine Treatment in Patients With Progressive Lacunar Infarction (CARBOGEN Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lacunar infarction is an ischemic stroke occurred by small perforating artery occlusion .&#xD;
      Twenty percent of ischemic stroke is lacunar infarction.&#xD;
&#xD;
      However, outcome of lacunar infarction is excellent, about 20-40% patients are suffered&#xD;
      neurological worsening.&#xD;
&#xD;
      Progressive lacunar infarction is associated poor functional outcome and neurological&#xD;
      deficit.&#xD;
&#xD;
      Currently, no treatment for progressive lacunar infarction is recommended on the guideline.&#xD;
&#xD;
      Several small study reported that phenylephrine and magnesium may be helpful for progressive&#xD;
      lacunar infarction.&#xD;
&#xD;
      Carbogen is a mixture of 5% CO2 with 95% O2. Carbogen is safe and it is used for the&#xD;
      treatment of sudden sensory neural hearing loss or ocular ischemia.&#xD;
&#xD;
      CO2 dilate cerebral arteriole and concentration of CO2 is correlated with cerebral blood&#xD;
      flow.&#xD;
&#xD;
      Lacunar infarction is small and perfused with marginal flow by neighboring perforating&#xD;
      arteriole.&#xD;
&#xD;
      Increased cerebral blood flow following dilation of cerebral arteriole by CO2 might halt and&#xD;
      revert progressive lacunar infarction.&#xD;
&#xD;
      Induced hypertension is alternative treatment of progressive lacunar infarction. Increasing&#xD;
      blood pressure also induce cerebral blood flow.&#xD;
&#xD;
      Phenylephrine is an α1 agonist, phenylephrine act on peripheral artery and little effect on&#xD;
      cerebral artery or heart.&#xD;
&#xD;
      Several studies reported that the effectiveness of phenylephrine on progressing stroke.&#xD;
&#xD;
      Therefore, this study will compare the effectiveness of carbogen versus phenylephrine in&#xD;
      lacunar infarction patients who suffered neurological worsening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is a single center, prospective, randomized, open-label trial with blinded end-point assessment (PROBE) design study.&#xD;
For the patients with neurological worsening after lacunar infarction, the carbogen group and the phenylephrine group will be randomized by 1: 1.&#xD;
Patients will be enrolled from April 2021 to December 2022 (based on the date of stroke).&#xD;
We will collect medical history, laboratory findings, neurological scores, and functional recovery.&#xD;
Functional recovery scores are performed by independent researchers in the blind state.&#xD;
All data is collected using e-CRF, and the image study will be anonymized and sent to the central adjudication.&#xD;
Central adjudication will review the image study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Three months after discharge, the independence assessment will be performed by the researcher who don't know the patients group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>percent improvement of NIHSS score in each group</measure>
    <time_frame>48 hours</time_frame>
    <description>(baseline NIHSS score-post-treatment NIHSS score)/baseline NIHSS score×100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>difference of NIHSS score in each group</measure>
    <time_frame>48 hours</time_frame>
    <description>baseline NIHSS score-post-treatment NIHSS score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>percent improvement of MRC score in each group</measure>
    <time_frame>within 48 hours</time_frame>
    <description>(baseline MRC score-post-treatment MRC score)/baseline MRC score×100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>difference of MRC score in each group</measure>
    <time_frame>within 48 hours</time_frame>
    <description>baseline MRC score-post-treatment MRC score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety outcome: Side effect</measure>
    <time_frame>within 7 days</time_frame>
    <description>Side effect (cerebral hemorrhage, myocardial infarction, Losing consciousness, difficulty breathing, dizziness, fatigue, headache, anxiety, etc)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety outcome: discontinuing patients</measure>
    <time_frame>within 7 days</time_frame>
    <description>Number of discontinuing patients due to side effects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison between groups by percent improvement of NIHSS score</measure>
    <time_frame>48 hours</time_frame>
    <description>(baseline NIHSS score-post-treatment NIHSS score)/baseline NIHSS score×100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between groups by difference of NIHSS score</measure>
    <time_frame>48 hours</time_frame>
    <description>baseline NIHSS score-post-treatment NIHSS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between groups by percent improvement in MRC score</measure>
    <time_frame>within 48 hours</time_frame>
    <description>(baseline MRC score-post-treatment MRC score)/baseline MRC score×100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between groups by difference of MRC score</measure>
    <time_frame>within 48 hours</time_frame>
    <description>baseline MRC score-post-treatment MRC score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional independence</measure>
    <time_frame>upon discharge, 3 months after onset</time_frame>
    <description>modified Rankin score 0 to 2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Carbogen group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenylephrine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carbogen</intervention_name>
    <description>Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes.</description>
    <arm_group_label>Carbogen group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phenylephrine</intervention_name>
    <description>Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.</description>
    <arm_group_label>Phenylephrine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥20 years&#xD;
&#xD;
          2. Anterior circulation progressive lacunar infarction.&#xD;
&#xD;
          3. Neurological worsening either 1 point in NIHSS score or MRC grade&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt;20&#xD;
&#xD;
          2. Cortical infarction&#xD;
&#xD;
          3. Posterior circulation lacunar infarction&#xD;
&#xD;
          4. Relevant artery stenosis more than 50% or occlusion&#xD;
&#xD;
          5. Moyamoya disease&#xD;
&#xD;
          6. Difficulty in inhalation of Carbogen (panic, severe anxiety disorder)&#xD;
&#xD;
          7. Drug allergy for phenylephrine&#xD;
&#xD;
          8. Persistent bradycardia (pulse rate &lt; 50 /min)&#xD;
&#xD;
          9. History of hemorrhagic stroke&#xD;
&#xD;
         10. Pre-stroke mRS ≥2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo Suk Nam, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Yonsei University College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyo Suk Nam, MD, PhD</last_name>
    <phone>82-2-2228-1617</phone>
    <email>HSNAM@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo Suk Nam, MD, PhD</last_name>
      <phone>82-2-2228-1617</phone>
      <email>HSNAM@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CO2</keyword>
  <keyword>carbogen</keyword>
  <keyword>phenylephrine</keyword>
  <keyword>lacunar infarction</keyword>
  <keyword>progressive stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Stroke, Lacunar</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

